Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
| Stanford University | OTHER |
| University of Washington | OTHER |
Not provided
Not provided
Not provided
Not provided
Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ria Treatment Platfrom | Experimental | The Ria Treatment Platform is a telehealth approach that includes medical assessment, prescription of clinically appropriate medications for alcohol use disorder, individual and group coaching, educational video modules, and monitoring of breath alcohol concentrations through a Bluetooth-enabled breathalyzer. |
|
| waitlist control | No Intervention | Patients in this arm will not be provided treatment during the study period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ria Treatment Platform | Combination Product | combined medication, coaching, education, and monitoring |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent of subjects without heavy drinking days | Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback. | Final 4 weeks of the 12-week trial period |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of abstinent days | Any drinking as assessed by the Timeline Followback | 12-week trial period |
| Liver function (ALT, AST, GGT) | Measures of liver function. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Mendelson, MD | Ria Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | United States |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition
Not provided
Not provided
Not provided
Not provided
| 12 weeks |